Toft Group Executive Search has placed Nico Pannacciulli, MD, PhD, as Executive Medical Director, Clinical Development with Intercept Pharmaceuticals in San Diego, California. Dr. Pannacciulli previously worked with Amgen as Clinical Research Medical Director, Bone Therapeutic Area and was later promoted to Global Development Leader. Before working with Amgen, Dr. Pannacciulli was the Director, Cardiovascular Clinical Research at Gilead Sciences. He also worked with Bristol-Myers Squibb as their Medical Director, CV/Metabolic. Earlier in his industry career, Dr. Pannacciulli was the Associate Director, Clinical Development at Amylin.
Dr. Pannacciulli received his MD from the University of Bari, Italy and his PhD in Endocrine and Metabolic Sciences from the University of Naples, Italy.
About Toft Group Executive Search
Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide. The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.
About Intercept Pharmaceuticals
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.